Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-003 first-line pembrolizumab ± lenvatinib in advanced melanoma
2018-002520-16Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2018; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-002520-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002520-16.